PHVS

MKT CAP:$2B

Pharvaris N.V.

Market Cap

$2B

Healthcare·Biotechnology·🇳🇱 Netherlands·NASDAQ

Healthcare·Biotechnology·🇳🇱·NASDAQ

Stock Price

$27.29+$0.81 (+3.06%)

Apr 23, 2026

Company Details

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II...

CEO

Berndt Axel Edvard Modig

IPO Date

Feb 5, 2021

Website

pharvaris.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$150M

EPS (Diluted)

-$2.88

Free Cash Flow

-$124M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q4 2025

May 12, 2026

PENDING

Q3 2025

Nov 12, 2025

$0EPS -$0.70

Q2 2025

Aug 12, 2025

$0EPS -$0.97

Q2 2024

Jun 28, 2024

$0EPS -$0.64

Q1 2022

Mar 31, 2022

$0EPS -$0.56

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 18	$0	$0	-$1M
Q3 18	$0	$0	-$1M
Q4 18	$0	$0	-$1M
Q1 19	$0	$0	-$2M
Q2 19	$0	$0	-$2M
Q3 19	$0	$0	-$2M
Q1 20	$0	$0	-$4M
Q2 20	$0	$0	-$7M
Q3 20	$0	$0	-$7M
Q1 21	$0	$0	-$14M
Q2 21	$0	$0	-$15M
Q4 21	$0	$0	-$19M
Q1 22	$0	$0	-$23M
Q2 24	$0	$0	-$40M
Q2 25	$0	$0	-$47M
Q3 25	$0	$0	-$46M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 18	-$1M	-$1M
Q3 18	-$1M	-$1M
Q4 18	-$1M	-$1M
Q1 19	-$2M	-$2M
Q2 19	-$2M	-$2M
Q3 19	-$2M	-$2M
Q1 20	-$3M	-$3M
Q2 20	-$4M	-$4M
Q3 20	-$8M	-$8M
Q1 21	-$12M	-$12M
Q2 21	-$14M	-$14M
Q4 21	-$15M	-$15M
Q1 22	-$21M	-$21M
Q2 24	-$32M	-$32M
Q2 25	-$35M	-$35M
Q3 25	-$36M	-$36M

Capital Expenditures

Quarter	CapEx
Q2 18	$0
Q3 18	$0
Q4 18	$0
Q1 19	$3.9K
Q2 19	$3.9K
Q3 19	$3.9K
Q1 20	$16.7K
Q2 20	$4.8K
Q3 20	$20.1K
Q1 21	$11.8K
Q2 21	$27.5K
Q4 21	$80.1K
Q1 22	$30.8K
Q2 24	$46.9K
Q2 25	$19.5K
Q3 25	$21.9K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 19	—	+85.7%
Q2 19	—	+85.7%
Q3 19	—	+85.7%
Q1 20	—	+201.0%
Q2 20	—	+185.9%
Q3 20	—	+213.3%
Q1 21	—	+491.4%
Q2 21	—	+292.0%
Q4 21	—	+183.6%
Q1 22	—	+208.9%
Q2 24	—	+190.3%
Q2 25	—	+217.3%
Q3 25	—	+144.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 18	$29.4K	—
Q3 18	$29.4K	—
Q4 18	$29.4K	—
Q1 19	$33.9K	—
Q2 19	$33.9K	—
Q3 19	$33.9K	—
Q1 20	$343.4K	—
Q2 20	$428.4K	—
Q3 20	$456.3K	—
Q1 21	$2M	—
Q2 21	$2M	—
Q4 21	$2M	—
Q1 22	$2M	—
Q2 24	$5M	—
Q2 25	$6M	—
Q3 25	$6M	—

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q2 18	$1M	$195.3K	—
Q3 18	$1M	$195.3K	—
Q4 18	$1M	$195.3K	—
Q1 19	$2M	$679.8K	—
Q2 19	$2M	$679.8K	—
Q3 19	$2M	$679.8K	—
Q1 20	$3M	$985.1K	—
Q2 20	$5M	$2M	—
Q3 20	$6M	$1M	—
Q1 21	$9M	$4M	—
Q2 21	$9M	$5M	—
Q4 21	$13M	$6M	$321.6K
Q1 22	$16M	$7M	—
Q2 24	$27M	$13M	—
Q2 25	$35M	$13M	—
Q3 25	$35M	$12M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$228M	$0	$228M
Q2 22	$235M	$0	$235M
Q3 22	$231M	$0	$231M
Q4 22	$189M	$0	$189M
Q1 23	$158M	$0	$158M
Q2 23	$210M	$0	$210M
Q3 23	$185M	$0	$185M
Q4 23	$457M	$0	$457M
Q1 24	$431M	$0	$431M
Q2 24	$402M	$0	$402M
Q3 24	$357M	$0	$357M
Q4 24	$328M	$0	$328M
Q1 25	$277M	$0	$277M
Q2 25	$233M	$0	$233M
Q3 25	$385M	$0	$385M
Q4 25	$341M	$0	$341M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 18	32M	0.0%	—
Q3 18	32M	0.0%	—
Q4 18	32M	0.0%	—
Q1 19	32M	0.0%	0.0%
Q2 19	32M	0.0%	0.0%
Q3 19	32M	0.0%	0.0%
Q1 20	32M	0.0%	0.0%
Q2 20	32M	0.0%	0.0%
Q3 20	32M	0.0%	0.0%
Q1 21	32M	-0.1%	-0.1%
Q2 21	33M	+4.1%	+4.0%
Q4 21	33M	+0.0%	+4.1%
Q1 22	33M	0.0%	+4.1%
Q2 24	54M	+62.8%	+69.5%
Q2 25	55M	+1.4%	+65.1%
Q3 25	62M	+13.8%	+87.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 18	—	—
Q3 18	—	—
Q4 18	—	—
Q1 19	—	—
Q2 19	—	—
Q3 19	—	—
Q1 20	—	—
Q2 20	—	—
Q3 20	—	—
Q1 21	$0	14
Q2 21	$0	14
Q4 21	$0	34
Q1 22	$0	34
Q2 24	$0	82
Q2 25	$0	108
Q3 25	$0	108

Revenue / Employee